Schizophrenia Clinical Trials in Lemon Grove, California

8 studies are recruiting for schizophrenia in Lemon Grove, California right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia

    The purpose of the study is to evaluate the relapse prevention of KarXT in the treatment of participants with Schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Local Institution - 0128, Lemon Grove, California
    Locations
    59 in total
    Run by
    Karuna Therapeutics, Inc., a Bristol Myers Squibb company

    See if you can join NCT07686263 on ClinicalTrials.gov

  2. A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia

    ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).

    Stage
    Phase 2
    Ages
    18 to 65
    Site
    Clinical Site, Lemon Grove, California
    Locations
    42 in total
    Run by
    MapLight Therapeutics

    See if you can join NCT07459647 on ClinicalTrials.gov

  3. A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

    Evaluate the efficacy and safety of Ulotaront (SEP-363856) in acutely psychotic subjects with schizophrenia

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Synergy San Diego Site, Lemon Grove, California
    Locations
    73 in total
    Run by
    Otsuka Pharmaceutical Development & Commercialization, Inc.

    See if you can join NCT06894212 on ClinicalTrials.gov

  4. Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia

    This is a Phase 3, randomized, double blind, placebo controlled, fixed dose, study designed to evaluate the efficacy, safety, tolerability, and of LB-102 versus placebo for the treatment of adult patients with an acute exacerbation of schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Synergy San Diego, Lemon Grove, California
    Locations
    13 in total
    Run by
    LB Pharmaceuticals Inc.

    See if you can join NCT07363577 on ClinicalTrials.gov

  5. NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia

    This study will evaluate the long-term safety of NBI-1117568 in adults with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, Lemon Grove, California
    Locations
    57 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07114874 on ClinicalTrials.gov

  6. Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia

    The main objective of the study is to evaluate NBI-1117568 compared with placebo in delaying relapse of symptoms of schizophrenia in adults who have a stable response after open-label treatment with NBI-1117568.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Neurocrine Clinical Site, Lemon Grove, California
    Locations
    20 in total
    Run by
    Neurocrine Biosciences

    See if you can join NCT07227818 on ClinicalTrials.gov

  7. Randomized Withdrawal Study in Patients With Schizophrenia

    The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia.

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Vanda Investigational Site, Lemon Grove, California
    Locations
    22 in total
    Run by
    Vanda Pharmaceuticals

    See if you can join NCT06961968 on ClinicalTrials.gov

  8. Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

    This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg or 50 mg once daily over 4 weeks, then in the long-term flexible doses 15-50mg daily over a period o…

    Stage
    Phase 3
    Ages
    18 to 65
    Site
    Reviva site, Lemon Grove, California
    Locations
    18 in total
    Run by
    Reviva Pharmaceuticals

    See if you can join NCT05184335 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.